26 year-old male dies of myocarditis four days after receiving his third booster shot

According to the autopsy report and death certificate obtained by the Defender, for this 26-year-old male "post-Pfizer Covid vaccination myocarditis has been identified to cause left ventricular dysfunction” that led to his death. 

At birth, he was diagnosed with a rare type of blood vessel abnormality inside the brain called Vein of Galen Malformation. This condition could be caused by mutations in RASA1 gene - involved in numerous physiological processes such as angiogenesis, cell proliferation, and apoptosis; regulator of immune B cells TGF-β and EPHB4 involved in cell migration.  He had 13 brain surgeries, endless MRIs, CAT scans, angiograms, pokes, and a final radiation treatment that was a success in eliminating the arteriovenous malformation (AVM).

He got his first and second doses of Pfizer vaccine as soon as his age group was eligible. He did not have any side effects. Almost 7 months later he received his third shot of BNT162b2 vaccine (batch FE3590). It caused some muscle soreness and fatigue. On the fourth day he developed a sore throat. He was feverish and had elevated heart rate. Since this was considered normal according to CDC guidelines no measures - other than Tylenol - were taken. He died in his chair 2 hours after a dinner. Apple watch data show that his heart rate was very high at first, but dropped into the 60s, which was low compared to usual 80s and 90s — and then it just stopped.


REFERENCES

Exclusive: Autopsy Confirms 26-Year-Old’s Death From Myocarditis Directly Caused by Pfizer COVID Vaccine • Children's Health Defense (childrenshealthdefense.org)

Autopsy Reveals Death of 26-Year-Old Man Who Developed Myocarditis was Due to Pfizer Vaccine – DC Weekly

Joseph-G-Keating-age-26-death-certificate-scaled.jpg (1920×2560) (childrenshealthdefense.org)


Comments

Post a Comment

Popular posts from this blog

A New Onset of Ulcerative Colitis post-2nd-breakthrough-COVID-19

Image
A 21-year-old non-smoking Caucasian male with a history of acute pancreatitis but no other medical issues or family history had two doses of the BNT162b2 mRNA COVID-19 vaccine.  Four months after the second dose he had his first episode of COVID-19. Although not hypoxic, he felt pretty unwell for a week, with a severe cough, fever, generalized body ache, headache, and loss of taste. He received the third dose of the vaccine two months after recovering from COVID. Nine months after the third dose, he had the second episode of COVID-19, during which he was mildly unwell for three days, recovered, and did not require any anti-viral medication or antibiotics. One week post the second episode of COVID-19, he developed diarrhea and abdominal pain. It then progressed to bloody diarrhea. Ulcerative colitis was diagnosed based on his clinical symptoms, biopsy changes, and the exclusion of other causes.  There are ten published case reports about the newly diagnosed ulcerative colitis associate
Read more

Navigating the Tripledemic: JN.1, RSV, and Flu Update

Image
The respiratory viruses are out there.  Wastewater viral activity levels for COVID-19 , as reported by the Centers for Disease Control and Prevention, have reached the highest point since the Omicron surge in 2022. The levels are also high in Canada . The three primary respiratory illnesses continue to circulate at very high levels. But despite the triple threat of  SARS-Cov-2, respiratory syncytial virus ( RSV ) and the flu , there is a notable lack of community attention.   JN.1 (Pirola,  BA.2.86 ,  with additional L455S mutation, descending from a  de-escalated  variant of concern BA.2), initially detected on August 25 2023, has evolved from a variant under monitoring to a  variant of interest. Variants like Acrux (XBB.2.3, that began to spread worldwide soon after WHO declared the end of the pandemic) are  no longer relevant , but a few now less prevalent variants such as  Centaurus  (BA.2.75) and XBB, a hybrid of Centaurus with BA.2 lineage, that  gave rise to  Eris , its descend
Read more

The offshoots of JN.1 in the Evolutionary Trajectory of COVID-19

Image
While the current SARS-COV-2 viral activity levels may seem reassuring ( back to the levels seen in October-November 2023 ), the evolving world of JN.1 offshoots, where the next generation of variants is taking shape, presents a compelling case for anticipating the potential challenges that lie ahead.  From the widespread presence of JN.1.16 across continents to the emerging dominance of JN.1.13 in the U.S., the current variant landscape is rapidly shifting, although the potential implications for the future are not quite clear.  The roots of the pandemic can be traced back to lineage A, with many initial sequences originating from China and subsequently spreading globally, including to regions such as South East Asia, Japan, South Korea, Australia, the USA, and Europe. Lineage B followed as the second major haplotype, with subsequent evolutions leading to the emergence of various sublineages. In 2020, we witnessed the emergence of variants such as Alpha (B.1.1.7) and Delta (B.1.617.2
Read more